Is Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record

Simply Wall St.01-23

If you are wondering whether Agios Pharmaceuticals at around US$28.66 is offering value or just noise, this article will walk through what the current price might really mean. The stock has returned ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605426525?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-23 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605426525","market":"nz","top_or_hot":-1,"title":"Is Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Agios Pharmaceuticals at around US$28.66 is offering value or just noise, this article will walk through what the current price might really mean. The stock has returned ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-pricing-reflect-its-recent-reb\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-23 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-pricing-reflect-its-recent-reb><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Agios Pharmaceuticals at around US$28.66 is offering value or just noise, this article will walk through what the current price might really mean. The stock has returned ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-pricing-reflect-its-recent-reb\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-pricing-reflect-its-recent-reb","article_id":"2605426525","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-pricing-reflect-its-recent-reb","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605426525","pubTimestamp":1769135285,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Agios Pharmaceuticals at around US$28.66 is offering value or just noise, this article will walk through what the current price might really mean.\nThe stock has returned 3.1% over the last 7 days and 16.6% over the last 30 days, while the 1 year return sits at negative 19.0%. This can catch the eye of investors thinking about changing risk and return trade offs.\nRecent coverage of Agios has focused on its position within the pharmaceuticals and biotech space and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","AGIO":"Agios Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Agios Pharmaceuticals(AGIO)的定价是否反映了其近期的反弹和长期业绩记录","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"AGIO":1.5},"content_text":"If you are wondering whether Agios Pharmaceuticals at around US$28.66 is offering value or just noise, this article will walk through what the current price might really mean. The stock has returned 3.1% over the last 7 days and 16.6% over the last 30 days, while the 1 year return sits at negative 19.0%. This can catch the eye of investors thinking about changing risk and return trade offs. Recent coverage of Agios has focused on its position within the pharmaceuticals and biotech space and how investors are reacting to its pipeline and cash profile. This context helps explain why short term gains sit alongside a 3 year return of negative 6.7% and a 5 year return of negative 36.9%. On our valuation checks, Agios has a value score of 2 out of 6. We will look at what traditional valuation methods say about that score, then finish with a more complete way to think about value that pulls everything together.  Agios Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Agios Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today, aiming to estimate what the entire stream of cash is worth in present dollar terms. For Agios Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections in $. The latest twelve months free cash flow is a loss of about $424.7 million. Analyst inputs and extrapolations then project annual free cash flows from 2026 through 2035, moving from projected losses, such as $251.8 million in 2026 and $211.7 million in 2027, to positive free cash flow of $117.2 million in 2030 and higher estimates beyond that year. Discounting this stream of projected cash flows back to today produces an estimated intrinsic value of about $114.71 per share. Compared with the recent share price around $28.66, the DCF output implies Agios might be about 75.0% undervalued on these assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Agios Pharmaceuticals is undervalued by 75.0%. Track this in your watchlist or portfolio, or discover 878 more undervalued stocks based on cash flows. AGIO Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Agios Pharmaceuticals. Approach 2: Agios Pharmaceuticals Price vs Sales For companies that are not currently profitable, the P/S ratio is often more useful than P/E, because it compares what investors are paying to the revenue being generated rather than to earnings that may be volatile or negative. What counts as a reasonable P/S ratio depends on what the market expects for growth and how risky those expectations look. Faster expected revenue growth or lower perceived risk can justify a higher P/S, while slower growth or higher uncertainty usually calls for a lower multiple. Agios Pharmaceuticals currently trades on a P/S of 37.31x. That sits well above the Biotechs industry average of 11.83x and the peer average of 7.26x. Simply Wall St also calculates a proprietary “Fair Ratio” of 0.00x for Agios, which is the P/S multiple you might expect once factors like earnings growth, industry, profit margin, market cap and company specific risks are accounted for. This Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it blends growth, risk, profitability, industry context and size into a single reference point. Set against this Fair Ratio, the current P/S of 37.31x suggests the shares are trading well above that model based level. Result: OVERVALUED NasdaqGS:AGIO P/S Ratio as at Jan 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1428 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Agios Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about a company linked directly to your assumptions for fair value, future revenue, earnings and margins. On Simply Wall St, Narratives live in the Community page and let you connect Agios Pharmaceuticals' business story to a forecast and then to a fair value estimate, in a format that is easy to compare with the current share price. That comparison between fair value and price can help you decide whether Agios looks attractive, fully priced or expensive based on your own view, and your Narrative automatically updates when fresh information such as news or earnings is added to the platform. For example, one Agios Narrative on the Community page might assume strong revenue growth, improving margins and a fair value well above US$28.66, while another could assume slower growth, more modest margins and a fair value closer to or below the current price, showing how different perspectives can coexist around the same stock. Do you think there's more to the story for Agios Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:AGIO 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605426525","isCrawlerRequest":true}